Synthesis of Indole-1,3,4-Oxadiazole Based Sulfonyl 1,2,3-Triazoles as Potent Anticancer and EGFR Inhibitors

Abstract

Herein, we synthesized some new indole-1,3,4-oxadiazole based sulfonyl 1,2,3-triazoles via a click chemistry approach and then characterized their structures by NMR, mass, and CHN analysis techniques. Later, the anticancer activity of the synthesized compounds was screened in vitro against different human cancer cell lines like MCF-7 and A-549, and the results were compared with the standard drug erlotinib. Most of the investigated compounds were found to be active against both cancer cell lines, MCF-7, and A-459. Specifically, compounds 2-(((1-(4-chloro-3,5-dimethoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)sulfonyl)-5-(1-methyl-1H-indol-3-yl)-1,3,4-oxadiazole and 2-(((1-(3,5-dichlorophenyl)-1H-1,2,3-triazol-4-yl)methyl) sulfonyl)-5-(1-methyl-1H-indol-3-yl)-1,3,4-oxadiazole had superior activity against MCF-7, and remarkable activity against A-549. Similarly, the compound 2-(((1-(3,5-dichlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)sulfonyl)-5-(1-methyl-1H-indol-3-yl)-1,3,4-oxadiazole showed more potent activity against EGFR and compound 2-(((1-(4-chloro-3,5-dimethoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)sulfonyl)-5-(1-methyl-1H-indol-3-yl)-1,3,4-oxadiazole showed equipotent activity against tyrosine kinase EGFR inhibitory activity.